Will I resolve more complex problems?
Different practices. One analysis. Your solution.
The Life Sciences Practice is composed of 30 specialists experienced in pharmaceutical and biotechnology law, food law, anti-monopoly law, healthcare and constitutional law.
We advise Polish and foreign entities in the pharmaceutical, healthcare, food and chemical sectors.
We specialise in strategic advice in the areas of reimbursement, distribution and telemedicine solutions.
Our clients are local government authorities, which we advise on the restructuring of the healthcare system.
We cooperate with sector organisations in consultation over legislative bills, preparing, e.g. opinions on whether bills comply with the Constitution and international law; we also participate in drawing up such regulations.
Our awareness of market practice enables us to render advice that gives a high level of legal safety and that is also effective in business terms. Where legal risks are identified, we try to propose solutions that will not only mitigate these risks but also achieve goals as near as possible to the client’s original intentions.
We run a legal blog where we regularly comment on legal changes affecting our clients' activity.
related articles
DZP ranks top in international ranking - Legal 500 EMEA 2025 results
News | 26.03.2025 In the latest ranking published by Legal 500, 18 DZP experts were highlighted as leading lawyers, and as many as 10 new lawyers were recognized by this prestigious ranking.
MIT Global Startup Workshop 2025
Event | 24.03.2025 Mateusz Mądry, Marek Paluch, and Maciej Zajda will participate in the conference organized by the Massachusetts Institute of Technology, which will be held in Poland for the first time.
DZP strengthens its position in Chambers Europe 2025 ranking
News | 20.03.2025 In the latest Chambers & Partners publication, as many as 20 DZP experts received individual recommendations. Our teams were recognized in 13 categories.
Top Trends Life Sciences 2025 Report
News | 12.03.2025 Our experts have prepared a report summarizing the key issues discussed at the DZP conference on upcoming regulatory changes and challenges in the pharmaceutical industry.